Worcester’s UMass Medical School announced on Tuesday that Mireli Fino will be the next executive vice chancellor for MassBiologics on July 1, leading the organization dedicated to improving worldwide health.
Fino is a biotech executive with nearly 30 years of experience in pharmaceutical manufacturing. She will join MassBiologics from Protein Sciences, a Sanofi company in Meriden, Conn., where she has worked since 2012 as senior vice president for manufacturing operations. Fino is the site head for Protein Sciences’ Pearl River and Meriden operations, where she oversees the production of vaccines and biopharmaceuticals at multiple sites and contract manufacturing organizations.
She previously worked for 16 years at New Jersey company Wyeth Pharmaceuticals and Pfizer, Inc. of New York City, in a variety of senior roles.
“Ms. Fino’s deep knowledge of pharmaceutical operations will help MassBiologics build upon its longstanding reputation in research, development and cGMP manufacturing of monoclonal antibody products and vaccines,” UMMS Chancellor Michael Collins said in a press release. “She will advance research and development of MassBiologics’ internal programs and of UMMS faculty and students while leading its manufacturing facilities in Mattapan and Fall River, and its industry relationships in alignment with the MassBiologics strategic plan.”
Mark Klempner, MD, who has led MassBiologics for the last nine years, will stay on and continue to lead research into therapies to prevent Lyme disease, diphtheria and enterotoxigenic E. coli.
